Related Experiment Video
Updated: Aug 9, 2026

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons
Published on: October 10, 2025
Peripheral neuropathy induced by microtubule-stabilizing agents
1Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889-5015, USA.
Abstract:
Microtubule-stabilizing agents (MTSAs), including the taxanes and epothilones, are effective chemotherapeutic agents for the treatment of many cancers. Neuropathy is a major adverse effect of MTSA-based chemotherapy, with severe peripheral neuropathy (grade 3 or 4) occurring in as many as 30% of patients treated with a MTSA. MTSA-induced neuropathy usually resolves gradually after cessation of the treatment. The most reliable method to accurately assess MTSA-induced neuropathy is by clinical evaluation, although additional techniques are being developed and evaluated. Among MTSA-induced neuropathy, the most extensively studied is that induced by taxanes; such a neuropathy usually presents as sensory neuropathy and is more common with paclitaxel than docetaxel. The incidence of MTSA-induced neuropathy seems to depend on the MTSA dose per treatment cycle, the schedule of treatment, and the duration of the infusion. Although there have been several small clinical trials with neuroprotective agents, early recognition and supportive care are the best approaches for prevention and management of MTSA-induced neuropathy. In the future, research should focus on elucidating the mechanism of MTSA-induced neuropathy, developing reliable in vivo and in vitro preclinical models to study MTSA-induced neuropathy, developing a more reliable grading system for MTSA-induced neuropathy, developing more reliable methods for evaluating MTSA-induced neuropathy, and evaluating the efficacy of potential neuroprotective agents in clinical trials.
Insights
Microtubule-stabilizing agents (MTSAs) effectively treat cancer but can cause severe neuropathy in up to 30% of patients. Early recognition and supportive care are crucial for managing this common chemotherapy side effect.
Area of Science:
- Oncology
- Neuroscience
- Pharmacology
Background:
- Microtubule-stabilizing agents (MTSAs), such as taxanes and epothilones, are vital chemotherapeutics.
- MTSA-based chemotherapy frequently leads to peripheral neuropathy, a significant adverse effect impacting up to 30% of patients.
- MTSA-induced neuropathy typically resolves post-treatment but necessitates careful management.
Purpose of the Study:
- To review the incidence, presentation, and management of microtubule-stabilizing agent-induced neuropathy.
- To highlight the importance of clinical evaluation in assessing MTSA-induced neuropathy.
- To identify future research directions for understanding and mitigating MTSA-induced neuropathy.
Main Methods:
- Literature review focusing on MTSA-induced neuropathy.
- Analysis of clinical data regarding incidence and severity.
- Examination of current and potential assessment techniques.
Main Results:
- Taxane-induced sensory neuropathy is the most studied form, more prevalent with paclitaxel than docetaxel.
- Neuropathy incidence correlates with MTSA dose, treatment schedule, and infusion duration.
- Clinical evaluation remains the gold standard for assessing MTSA-induced neuropathy.
Conclusions:
- Early recognition and supportive care are paramount for preventing and managing MTSA-induced neuropathy.
- Further research is needed to elucidate mechanisms, develop preclinical models, and evaluate neuroprotective agents.
- Improved grading systems and evaluation methods are essential for future clinical trials.
Related Concept Videos
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules
Destabilization of Microtubules
Diabetic Neuropathy
Microtubule Associated Proteins (MAPs)
Microtubule Instability
